Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.

Autor: Cosmi, B.1,2 (AUTHOR) benilde.cosmi@unibo.it, Giannella, M.3 (AUTHOR), Fornaro, G.3 (AUTHOR) giacomofornaro1990@gmail.com, Cristini, F.4 (AUTHOR), Patacca, A.4 (AUTHOR), Castagna, A.5 (AUTHOR), Mazzaferri, F.6 (AUTHOR), Testa, S.7 (AUTHOR), Pan, A.8 (AUTHOR), Lupi, M.8 (AUTHOR), Brambilla, P.8 (AUTHOR), Montineri, A.9 (AUTHOR), Frattima, S.10 (AUTHOR), Bignami, E. G.11 (AUTHOR), Salvetti, M.12 (AUTHOR), De Stefano, G.13 (AUTHOR), Grandone, E.14,15 (AUTHOR), Di Perri, G.16 (AUTHOR), Rozzini, R.17 (AUTHOR), Stella, A.18 (AUTHOR)
Zdroj: BMC Infectious Diseases. 10/24/2023, Vol. 23 Issue 1, p1-13. 13p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje